Navigation Links
Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA

GAITHERSBURG, Md. and CARLSBAD, Calif., April 18, 2007 /PRNewswire-FirstCall/ -- Micromet, Inc. and MedImmune, Inc. today announced data from a preclinical study in which BiTE(R) molecules targeting carcinoembryonal antigen (CEA) were shown to prevent subcutaneous tumor growth and formation of lung metastases. An established marker for tumor progression, CEA is frequently expressed on breast, colon and other human carcinomas. These data, presented yesterday in a poster session at the 2007 Annual Meeting of the American Association for Cancer Research (AACR), augment a growing body of preclinical and clinical research about the potential anti-cancer activity of BiTE molecules.

BiTE molecules represent a novel class of drugs that function as bi- specific T-cell engagers. They are unique in their ability to enable the body's killer T cells to recognize and attack tumor and target cells, leaving normal cells unharmed. In addition to demonstrating in vitro and in vivo anti- tumor activity, certain CEA-specific BiTE molecules also showed resistance to inhibition by soluble CEA. Because a soluble form of CEA is released from the surface of normal and tumor cells into the bloodstream, BiTE molecules targeting the antigen must not be inhibited by soluble CEA.

"In a joint effort, researchers at Micromet and MedImmune have developed CEA BiTE molecules that appear to be highly potent and to ignore levels of soluble CEA present in cancer patients while continuing to destroy tumor cells," said Patrick Baeuerle, Ph.D., Chief Scientific Officer at Micromet.

CEA is the second target in the research collaboration between Micromet and MedImmune against which new BiTE molecules were successfully generated and tested. The first target is the tyrosine kinase receptor EphA2, which is frequently overexpressed on a wide variety of solid tumors. Research published April 15, 2007 in Cancer Research demonstrated that
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
2. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
3. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
4. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
5. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
6. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
7. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
8. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
9. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
10. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
11. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
Post Your Comments:
(Date:10/6/2008)...ard-winning video clips feature children, parents ... studies, BETHESDA, Md., Oct. 6 /PRNewswire-USNew...cines, research in children saves lives and improv...m the National Institutes of,Health (NIH), "Childr...linicalStudies.nhlbi.nih.gov ), offers parents and...
(Date:10/6/2008)...ata from SONIC Trial Showed REMICADE Therapy is Mo...ucosal Healing Compared with Standard ...la., Oct. 6 /- Data presented for the...th Crohn,s Disease Naive to,Immunomodulators and B...nto,the approach to care of patients with moderate...
(Date:10/6/2008)... - Conference Call Scheduled for 9:00 AM E... -- Dendreon Corporation (Nasdaq:,DNDN) announced ...alysis of,the Phase 3, randomized, double-blind, p...te AdenoCarcinoma Treatment, also known as D9902B)...efficacy of the,investigational active cellular im...
(Date:10/6/2008)...esign Concept of Other Product - Company,s Bioabso...posium, HONG KONG, Oct. 6 /- Data fr...ro-healing stent, OrbusNeich,s Genous Bio-engineer...nscatheter Cardiovascular,Therapeutics symposium, ... M.D., Ph.D., of the Academic Medical Center in,Am...
Breaking Medicine Technology:Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3BD to Present at the Leerink Swann Molecular Diagnostics Roundtable Conference 15186 1Mens Health Guide for Ages 40 60 Launched by NHS Choices 15182 1Researchers urge ethics guidelines for human genome research 15179 1Researchers urge ethics guidelines for human genome research 15179 2AT 26T Announces Grant to Center on Aging University of Miami Miller School of Medicine 15177 1AT 26T Announces Grant to Center on Aging University of Miami Miller School of Medicine 15177 2AT 26T Announces Grant to Center on Aging University of Miami Miller School of Medicine 15177 3
(Date:10/6/2008)...t against childhood obesity, researcher notes , ...ee-quarters of middle schools have vending machine...study finds. , The research demonstrates that t...and "that those vending machines don,t always have...rus, a registered dietitian with the Center for Ob...
(Date:10/6/2008)...wire-FirstCall/ -- HealthSouth,Corporation (NYSE: ...ly,publicized investor meeting in New York City. P...30 a.m. EST at the Grand Hyatt New York, located a... follows:, 8:00 a.m. Continental Breakfast 8...ive Officer -- HealthSouth Overview a...
(Date:10/6/2008)...nel and their family members can take,anonymous on...STON, Oct. 6 /PRNewswire-USNewswire/ -- Military l...their families that are unique and,difficult. Some...atters get,worse and one problem can trigger other...check things out to see what is really happening.,...
(Date:10/6/2008)...University of California, San Diego School of Medi...ts bolsters production of a protective chemical no...n infections that are a common result of atopic de...study led by Richard Gallo, M.D., Ph.D., professo...logy at the UCSD School of Medicine and the Dermat...
Breaking Medicine News(10 mins):Health News:Vending Machines Found in Most Middle Schools 2Health News:HealthSouth to Hold Investor Meeting November 10, 2008 2Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 2Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 3Health News:Oral vitamin D may help prevent some skin infections 2
...artmouth Medical School investigators are learning...levels found in drinking water in many areas of th...aper published online on Dec. 2 in the journal Che...ort that three different steroid hormones all show...
... new study finds that the anti-craving drug, Naltr... negative moods and women who are trying to quit s...st step towards individualized medicine, scientist...nicotine addiction and in treatment. Researchers...
...n experimental epilepsy drug, lacosamide, develope... reducing the frequency of seizures in patients// ...n Monday following the results of a phase 3 trial....were presented at the North American Regional Epil...
... Canadian Study finds that adolescence boys are at... the same age.// Researchers have found that the s...before adulthood. Cardiologists say that smoking, ...ome of the factors for the cause of high blood pre...
Other Medicine News:Health News:Low Doses Of Arsenic Have Broad Impact On Hormone Activity – Says A Researc 2Health News:Low Doses Of Arsenic Have Broad Impact On Hormone Activity – Says A Researc 3Health News:Teen Boys At Greater Risk To High Blood Pressure Than Girls 2
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: